[go: up one dir, main page]

NO20070775L - Baerer for medikamenter for oppnaelse av oral biotilgjengelighet - Google Patents

Baerer for medikamenter for oppnaelse av oral biotilgjengelighet

Info

Publication number
NO20070775L
NO20070775L NO20070775A NO20070775A NO20070775L NO 20070775 L NO20070775 L NO 20070775L NO 20070775 A NO20070775 A NO 20070775A NO 20070775 A NO20070775 A NO 20070775A NO 20070775 L NO20070775 L NO 20070775L
Authority
NO
Norway
Prior art keywords
medications
carriers
oral bioavailability
polypeptide
obtaining oral
Prior art date
Application number
NO20070775A
Other languages
English (en)
Norwegian (no)
Inventor
Juergen Frevert
Thomas Stibora
Original Assignee
Biotecon Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Therapeutics Gmbh filed Critical Biotecon Therapeutics Gmbh
Publication of NO20070775L publication Critical patent/NO20070775L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20070775A 2004-07-22 2007-02-09 Baerer for medikamenter for oppnaelse av oral biotilgjengelighet NO20070775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004035606A DE102004035606A1 (de) 2004-07-22 2004-07-22 Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
PCT/DE2005/001290 WO2006010360A2 (fr) 2004-07-22 2005-07-22 Vehicule permettant d'obtenir des medicaments a biodisponibilite orale

Publications (1)

Publication Number Publication Date
NO20070775L true NO20070775L (no) 2007-04-18

Family

ID=35482323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070775A NO20070775L (no) 2004-07-22 2007-02-09 Baerer for medikamenter for oppnaelse av oral biotilgjengelighet

Country Status (13)

Country Link
EP (1) EP1768701A2 (fr)
JP (1) JP2008506724A (fr)
KR (1) KR20070047786A (fr)
CN (1) CN101340932A (fr)
AU (1) AU2005266739A1 (fr)
BR (1) BRPI0513715A (fr)
CA (1) CA2574124A1 (fr)
DE (1) DE102004035606A1 (fr)
IL (1) IL180229A0 (fr)
MX (1) MX2007000421A (fr)
NO (1) NO20070775L (fr)
RU (1) RU2006147284A (fr)
WO (1) WO2006010360A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008169166A (ja) * 2007-01-14 2008-07-24 Tokyo Univ Of Agriculture & Technology 糖結合性ポリペプチド、複合材料、及び薬剤送達システム
JP2009132686A (ja) * 2007-10-26 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
WO2009131435A1 (fr) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Lieur contenant de la bungarotoxine et un peptide de liaison
WO2011075500A2 (fr) * 2009-12-18 2011-06-23 Allergan, Inc. Stabilisation d'agents thérapeutiques pour faciliter l'administration
WO2013010782A2 (fr) 2011-07-15 2013-01-24 Nxp.B.V. Commande d'un convertisseur résonant
US10633643B2 (en) * 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914984D0 (en) * 1989-06-29 1989-08-23 Animal Health Inst Nucleotide sequences
CA2239909A1 (fr) * 1995-12-13 1997-07-03 President And Fellows Of Harvard College Utilisation de peptides de toxine et/ou de marqueurs d'affinite pour l'introduction de composes dans des cellules
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9824282D0 (en) * 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2003061694A1 (fr) * 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins

Also Published As

Publication number Publication date
WO2006010360A3 (fr) 2007-12-27
BRPI0513715A (pt) 2008-05-13
KR20070047786A (ko) 2007-05-07
CN101340932A (zh) 2009-01-07
CA2574124A1 (fr) 2006-02-02
EP1768701A2 (fr) 2007-04-04
JP2008506724A (ja) 2008-03-06
DE102004035606A1 (de) 2006-03-30
MX2007000421A (es) 2007-03-28
AU2005266739A1 (en) 2006-02-02
RU2006147284A (ru) 2008-08-27
WO2006010360A2 (fr) 2006-02-02
IL180229A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20070775L (no) Baerer for medikamenter for oppnaelse av oral biotilgjengelighet
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
NO20061026L (no) Nye insulinderivater
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
WO2006113546A3 (fr) Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
NO20090875L (no) Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner
WO2006066024A3 (fr) Motifs de famille de polypeptides pancreatiques, polypeptides et leurs methodes
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ATE414535T1 (de) Trägerproteine für impfstoffe
NO20044564L (no) Fremgangsmater for behandling av nekrotiserende enterocolit
ATE446314T1 (de) Methode zur reinigung von fsh
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
DK1844072T3 (da) MHC-oligomer og fremgangsmåde til fremstilling deraf
NO20030231L (no) Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter
NO20064034L (no) Makrolider og fremgangsmater for a fremstille disse
NO20053986L (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
MX2009003300A (es) Vectores de rhinovirus recombinantes.
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
ATE512158T1 (de) Differenziell geschützte, orthogonale lanthionintechnologie
UA89800C2 (en) Acylated nonadepsipeptides used as lysobactin derivatives
DK1577320T3 (da) Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
NO20014788D0 (no) En sammensetning for senkning av konsentrasjonen av sykdomsfremkallende tarmpeptider

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application